First Study of Neural Cells for Stroke Shows Promise Sue Hughes
May 7, 2015
https://www.facebook.com/pages/Aplicación-Células-Madres/157137874472617
The first study of human neural stem cells delivered directly to the brain in patients with stroke has shown no major harmful cell-related effects over 2 to 4 years' follow-up, with a suggestion of slight improvements in patient functionality.
Presenting the phase 1 study at the inaugural European Stroke Organisation (ESO) Conference 2015, Keith Muir, MD, University of Glasgow, United Kingdom, concluded that there were "sustained small neurological and functional improvements in most participants post-procedure" and that a phase 2 trial is warranted.
"There were a few adverse events from the neurosurgical procedures and anesthesia in elderly people," Dr Muir toldMedscape Medical News. "But in terms of efficacy, most patients improved. NIHSS [National Institutes of Health Stroke Scale] scores improved in almost all patients, with an average significant 2-point reduction over 2 years."
Dr Keith Muir
He cautioned that the improvements seen could not definitely be attributed to the cells, "but we selected patients a long time after stroke and usually these patients do not improve much."
May 7, 2015
https://www.facebook.com/pages/Aplicación-Células-Madres/157137874472617
The first study of human neural stem cells delivered directly to the brain in patients with stroke has shown no major harmful cell-related effects over 2 to 4 years' follow-up, with a suggestion of slight improvements in patient functionality.
Presenting the phase 1 study at the inaugural European Stroke Organisation (ESO) Conference 2015, Keith Muir, MD, University of Glasgow, United Kingdom, concluded that there were "sustained small neurological and functional improvements in most participants post-procedure" and that a phase 2 trial is warranted.
"There were a few adverse events from the neurosurgical procedures and anesthesia in elderly people," Dr Muir toldMedscape Medical News. "But in terms of efficacy, most patients improved. NIHSS [National Institutes of Health Stroke Scale] scores improved in almost all patients, with an average significant 2-point reduction over 2 years."
Dr Keith Muir
He cautioned that the improvements seen could not definitely be attributed to the cells, "but we selected patients a long time after stroke and usually these patients do not improve much."